Merck (NYSE:MRK) reported multiple positive Phase 3 results for KEYTRUDA-based combinations in renal cell carcinoma, bladder ...

Merck (NYSE:MRK) reported new Phase 3 data for belzutifan based WELIREG regimens in renal cell carcinoma, showing meaningful ...

ASCENT-04 randomized PD-L1–positive, untreated mTNBC to sacituzumab govitecan–pembrolizumab versus chemo–pembrolizumab, yielding a 3.4-month median PFS improvement (HR 0.65). Front-loading an ...

Three prominent names across the biopharma and consumer staples spaces offer the potential for value plays with room for ...

Federal judge sentences Houston man for selling fake cancer-fighting drug.

Practice-changing data in endometrial cancer support checkpoint inhibitor–chemotherapy combinations, extending ...

A 45-year-old man has been sentenced to prison for his role in selling tens of thousands of dollars' worth of counterfeit oncology pharmaceuticals into the United States, according to a news release.

Merck said on Monday it would split its business into two, creating ⁠a division for its cancer franchise while grouping its ​non-oncology treatments separately.

The therapeutic landscape for cutaneous T-cell lymphoma (CTCL) is undergoing a significant shift with the emergence of denileukin diftitox (Lymphir), the first systemic treatment ...

Explore the latest colorectal cancer treatment advances, from precision oncology and immunotherapy to ADCs, bispecifics, and T-cell engagers.

Oncology projects currently take up about 40% of Pfizer’s overall R&D budget. | After steering positive key pivotal readouts for a trio of Novartis’ blockbusters, Jeff Legos is now tasked with ...